Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + FOLFOX4 vs FOLFOX4 in first-line RAS wild-type metastatic colorectal cancer (China)
CTR20132642Phase 3Active
- Sponsor
- Merck KGaA
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cetuximab in colorectal cancer (CRC), sponsored by Merck KGaA. Started Sep 2014; status: active.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20132642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132642.